… Antigene PNA binds to complementary sequence in DNA … downregulation of translocated
c-myc with a specific PNA, can … , evaluation of pharmacokinetic parameters for PNA to an in …

… at distinct cis-regulatory sequences and act as integrative nodes … The compound showed
promising pharmacokinetic … chemical character is identical in both the c-Myc-Max X-ray dimer …

… regulation of MYC expression also offers a promising … G4 structures, pharmacokinetic studies
have highlighted a … inhibitors on targeted transcriptional regulation: while pan-BET inhibitor …

… , where the MYC proto-oncogene (c-myc) is translocated into the … MYCi975 shows favorable
pharmacokinetics and in vivo … with a complementary peptide nucleic acid (PNA) sequence to …

… As with other synthetic analogs, PNAs bind to complementary … 56] and PNAs designed to
bind to the second exon of the c-Myc … in PNAs such as the γtcMP-PNAs were promising, these …

… to assess the safety, pharmacokinetics (PK) and preliminary … , was used as a complementary
surrogate measure of tumor … -to-use solution of anti-c-MYC (Y69) rabbit monoclonal primary …

… and unfavorable pharmacokinetics [14-16]. Unmodified … structure of a self-complementary
PNA–PNA duplex [45]. Taken … In BRG cells at 10 μM concentration, PNA–NLS targeting c-myc …

… , including poor pharmacokinetic properties, insufficient … target expression of Mcl-1, c-Myc,
and Survivin was observed at … Based on these promising preclinical results, we conducted …

… One of the most attractive targets for cancer therapy is c-MYC. This oncogenic transcription
… Different c-MYC isoforms are generated due to alternative translation initiation start sites; …

… gene location by sequence complementarity and regulate … to evaluate MRX34 safety,
pharmacokinetics and clinical activity. … c-Myc is a multifunctional transcription factor considered to …